Related references
Note: Only part of the references are listed.Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury
Bahjat Al-Ani et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2023)
Diabetic cardiomyopathy attenuated the protective effect of ischaemic post-conditioning against ischaemia-reperfusion injury in the isolated rat heart model
Gino A. Kurian et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2023)
The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy
Malak Almutairi et al.
CANADIAN JOURNAL OF CARDIOLOGY (2021)
The sphingosine-1-phosphate receptor modulator, FTY720, prevents the incidence of diabetes in Spontaneously Diabetic Torii rats
Kazuma Kobayashi et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2021)
BH4 Increases nNOS Activity and Preserves Left Ventricular Function in Diabetes
Ricardo Carnicer et al.
CIRCULATION RESEARCH (2021)
Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
Nguyen Ngoc Trang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Novel Insights Into Molecular Mechanism of Mitochondria in Diabetic Cardiomyopathy
Jing Bai et al.
FRONTIERS IN PHYSIOLOGY (2021)
Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice
Weikun Jia et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial
Ricardo Ladeiras-Lopes et al.
ENDOCRINE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
SIRT6, A MAMMALIAN DEACYLASE WITH MULTITASKING ABILITIES
Andrew R. Chang et al.
PHYSIOLOGICAL REVIEWS (2020)
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
Hidekazu Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Estrogenic control of mitochondrial function
Carolyn M. Klinge
REDOX BIOLOGY (2020)
Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway
Zhen Yang et al.
FRONTIERS IN PHYSIOLOGY (2020)
NAD+administration decreases microvascular damage following cardiac ischemia/reperfusion by restoring autophagic flux
You-Jun Zhang et al.
BASIC RESEARCH IN CARDIOLOGY (2020)
High-glucose-induced apoptosis, ROS production and pro-inflammatory response in cardiomyocytes is attenuated by metformin treatment via PP2A activation
Gang Cheng et al.
JOURNAL OF BIOSCIENCES (2020)
Reduced reticulum-mitochondria Ca2+ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy
Maya Dia et al.
BASIC RESEARCH IN CARDIOLOGY (2020)
A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction
Peng Qian et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Reduced fatty acid uptake aggravates cardiac contractile dysfunction in streptozotocin-induced diabetic cardiomyopathy
Yogi Umbarawan et al.
SCIENTIFIC REPORTS (2020)
Cardioprotective Effect of Decorin in Type 2 Diabetes
Fuqiong Chen et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Sirt6-Mediated Endothelial-to-Mesenchymal Transition Contributes Toward Diabetic Cardiomyopathy via the Notch1 Signaling Pathway
Yan Zhang et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Calcium Homeostasis in Ventricular Myocytes of Diabetic Cardiomyopathy
Lina T. Al Kury
JOURNAL OF DIABETES RESEARCH (2020)
Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy
Vajir Malek et al.
CARDIOVASCULAR RESEARCH (2019)
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Qingguo Lu et al.
BIOSCIENCE REPORTS (2019)
Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications
Agha Zeeshan Mirza et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study
Neale D. Cohen et al.
INTERNAL MEDICINE JOURNAL (2019)
Activation of the PP2A catalytic subunit by ivabradine attenuates the development of diabetic cardiomyopathy
Guang-Feng Zuo et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy
Vajir Malek et al.
PHARMACOLOGICAL REPORTS (2019)
Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
Wei Ding et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Mei Xue et al.
CLINICAL SCIENCE (2019)
Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis
Qing Ge et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2019)
Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases
Stephane Demine et al.
CELLS (2019)
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum et al.
BASIC RESEARCH IN CARDIOLOGY (2019)
GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes)
Michael Halim et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway
Lujin Wu et al.
AGING CELL (2018)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
N. H. Cho et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss
Sarah Weske et al.
NATURE MEDICINE (2018)
The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis
Selma Bouthoorn et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
Xiaowei Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats
Wenjuan Liu et al.
JOURNAL OF DIABETES RESEARCH (2018)
Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB
Sura Al Zoubi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
The Effects of Carvedilol on Cardiac Function and the AKT/XIAP Signaling Pathway in Diabetic Cardiomyopathy Rats
Wencheng Zheng et al.
CARDIOLOGY (2017)
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Steve Bain et al.
DIABETES OBESITY & METABOLISM (2017)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Carvedilol and antioxidant proteins in a type I diabetes animal model
Catia V. Diogo et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2017)
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Allison B. Goldfine et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease
Amin Polzin et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2017)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes
Lama Fawaz Pharaon et al.
TOXICOLOGY LETTERS (2017)
Metformin attenuates ER stress-induced mitochondrial dysfunction
Qun Chen et al.
TRANSLATIONAL RESEARCH (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Calcium Signaling Series
David A. Eisner et al.
CIRCULATION RESEARCH (2017)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Guanghong Jia et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes A Systematic Review and Meta-analysis
Nisa M. Maruthur et al.
ANNALS OF INTERNAL MEDICINE (2016)
Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis
Dina M. Khodeer et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2016)
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Manasi S. Shah et al.
CIRCULATION RESEARCH (2016)
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
William B. White et al.
DIABETES CARE (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Jan W. Eriksson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy
Chowdhury S. Abdullah et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?
Maximilian E. Hoelscher et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Stella Bernardi et al.
JOURNAL OF DIABETES RESEARCH (2016)
New Molecular Insights of Insulin in Diabetic Cardiomyopathy
Francisco Westermeier et al.
FRONTIERS IN PHYSIOLOGY (2016)
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes
Ju-Young Moon et al.
PLOS ONE (2016)
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
Michel Komajda et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Protective effect of pioglitazone on cardiomyocyte apoptosis in low-dose streptozotocin & high-fat diet-induced type-2 diabetes in rats
Uma Bhandari et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Richard E. Gilbert et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats
N. N. Hamouda et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
Diabetes Alters the Expression and Translocation of the Insulin-Sensitive Glucose Transporters 4 and 8 in the Atria
Zahra Maria et al.
PLOS ONE (2015)
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Kerstin Nowotny et al.
BIOMOLECULES (2015)
I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice
Shao-Liang Chen et al.
BMC CARDIOVASCULAR DISORDERS (2014)
Insulin Stimulates Mitochondrial Fusion and Function in Cardiomyocytes via the Akt-mTOR-NF kappa B-Opa-1 Signaling Pathway
Valentina Parra et al.
DIABETES (2014)
Molecular mechanisms of diabetic cardiomyopathy
Heiko Bugger et al.
DIABETOLOGIA (2014)
The Immunosuppressant FTY720 Prolongs Survival in a Mouse Model of Diet-induced Coronary Atherosclerosis and Myocardial Infarction
Guanying Wang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Anila K. Madiraju et al.
NATURE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Diabetes Mellitus and Inflammation
Eric Lontchi-Yimagou et al.
CURRENT DIABETES REPORTS (2013)
Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community
Sotero P. Romero et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren
Amil M. Shah et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Nancy J. Brown
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Duration of Diabetes and Risk of Ischemic Stroke The Northern Manhattan Study
Chirantan Banerjee et al.
STROKE (2012)
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials
Adrian V. Hernandez et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2011)
Microvascular Coronary Dysfunction in Women-Pathophysiology, Diagnosis, and Management
Kamlesh Kothawade et al.
CURRENT PROBLEMS IN CARDIOLOGY (2011)
Improvement of Cardiac Functions by Chronic Metformin Treatment Is Associated With Enhanced Cardiac Autophagy in Diabetic OVE26 Mice
Zhonglin Xie et al.
DIABETES (2011)
The renin-angiotensin-aldosterone system and glucose homeostasis
James Matthew Luther et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes
Charlotte Andersson et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Kevin M. Pantalone et al.
ACTA DIABETOLOGICA (2009)
Tissue-Specific Remodeling of the Mitochondrial Proteome in Type 1 Diabetic Akita Mice
Heiko Bugger et al.
DIABETES (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
Vivek P. Singh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis
Hironori Hayashi et al.
HYPERTENSION RESEARCH (2008)
Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP
Yong Deuk Kim et al.
DIABETES (2008)
Diabetes and mortality following acute coronary syndromes
Sean M. Donahoe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes
Vivek P. Singh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Advanced glycation end products - Sparking the development of diabetic vascular injury
Alison Goldin et al.
CIRCULATION (2006)
Predictors of mortality and morbidity in patients with chronic heart failure
SJ Pocock et al.
EUROPEAN HEART JOURNAL (2006)
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
DT Eurich et al.
DIABETES CARE (2005)
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure - An observational study
FA Masoudi et al.
CIRCULATION (2005)
The incidence of congestive heart failure associated with antidiabetic therapies
GA Nichols et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Screening for heart disease in diabetic subjects
ZY Fang et al.
AMERICAN HEART JOURNAL (2005)
Insulin-treated dia betes is associated with a marked increase in mortality in patients with advanced heart failure
S Smooke et al.
AMERICAN HEART JOURNAL (2005)
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF
PC Deedwania et al.
AMERICAN HEART JOURNAL (2005)
Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus
JK Boyer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death - A population-based study of 13000 men and women with 20 years of follow-up
T Almdal et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers
M Bobbio et al.
JOURNAL OF CARDIAC FAILURE (2003)
Effect of carvedilol on the morbidity of patients with severe chronic heart failure - Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study
M Packer et al.
CIRCULATION (2002)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure
E Erdmann et al.
EUROPEAN JOURNAL OF HEART FAILURE (2001)
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
P Raskin et al.
DIABETES CARE (2001)
Myocardial cell death in human diabetes
A Frustaci et al.
CIRCULATION RESEARCH (2000)
Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans
SY Osei et al.
HYPERTENSION (2000)
Share Paper
